In search of biological markers for Alzheimer's disease;A la recherche de marqueurs biologiques de la maladie d'Alzheimer

Annales de Biologie Clinique

Volumn 58, Issue 5, 2000, Pages 581-593

  Couderc, R ^a  

^a Service de Biochimie   (France)

Author keywords

Alzheimer's disease; Biological markers; Dementia

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN RECEPTOR; TAU PROTEIN;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ANIMAL; BIOLOGICAL MONITORING; COMPARATIVE STUDY; COST; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; GENETIC MARKER; GENETIC RISK; GENOTYPE; HUMAN; MOUSE; MUTATION; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; RELIABILITY; REPRODUCIBILITY; REVIEW; RISK FACTOR; SCREENING; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALPHA-MACROGLOBULINS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMAL; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; COMPARATIVE STUDY; DIAGNOSIS, DIFFERENTIAL; ENGLISH ABSTRACT; GENETIC MARKERS; GENOTYPE; HUMAN; MICE; MICE, TRANSGENIC; MIDDLE AGE; MUTATION; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 0033770919     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Biological markers and diagnostic investigations in Alzheimer's disease
2. The development of biological markers for the diagnosis of Alzheimer's disease
3. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working
4. The search for diagnostic and progression markers in AD: So near but still too far
5. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
6. Proteolytic processing of Alzheimer's disease associated proteins
7. Constitutive and regulated alpha-secretase cleavase of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease
8. Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease
9. Two transmembrane aspartates in presenilin-1 required for preseninlin endoproteolysis and gamma-secretase activity
10. The involvement of the ubiquitin system in Alzheimer's disease
11. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation
12. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
13. Ubiquitin, cellular inclusions and their role in neurodegeneration
14. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles
15. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments
16. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
17. Apolipoprotein E-epsilon 4 allele and Alzheimer's disease
18. Apolipoprotein E4: Phenotype in patients with Alzheimer's disease
19. Isoform 4 of apolipoprotein E and Alzheimer disease. Specificity and clinical study
20. Apolipoprotein E and Alzheimer's disease
21. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease
22. Apolipoprotein E and its alleles in healthy subjects and in atherosclerosis
23. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium
24. Apolipoprotein E genetic variation and Alzheimer's disease: A meta-analysis
25. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides
26. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease
27. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene
28. A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele
29. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia
30. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: Independent risk and linkage disequilibrium with the known APOE polymorphism
31. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease
32. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene
33. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
34. Genetic association of an alpha2-macroglobulin (Va1100011e) polymorphism and Alzheimer's disease
35. Neurobiological correlates of a putative risk allele for Alzheimer's disease on chromosome 12q
36. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease
37. Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease
38. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing
39. Cerebrospinal fluid levels of A beta 42 and tau: Potential markers of Alzheimer's disease
40. Biological markers for the diagnosis of Alzheimer's disease
41. Phosphorylated Tau in human cerebrospinal fluid is a diagnostic marker for Alzeimer's disease
42. Sensitivity, specificity, and stability of CSF-Tau in AD in a community-based patient sample
43. Longitudinal stability of CSF Tau levels in Alzheimer patients
44. Three-year follow-up of cerebrospinal fluid Tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease
45. Cerebrospinal fluid Tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
46. Cerebrospinal fluid Tau protein shows a better discrimination in young old (< 70 years) than in old patients with Alzheimer's disease compared with controls
47. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
48. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF
49. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease
50. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease
51. Alzheimer disease, markers in the cerebrospinal fluid: Support of physiopathologic hypotheses
52. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid
53. Combined assessment of Tau and neuronal thread protein in Alzheimer's disease CSF
54. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease
55. Differential level of platelet amyloid beta precursor protein isoforms: An early marker for Alzheimer disease
56. Platelet APP isoform ratios correlate with declining cognition in AD
57. Altered amyloid protein processing in platelets of patients with Alzheimer disease